Policy & Regulation
Innogen Pharmaceuticals licenses Efsubaglutide Alfa rights to Arcera Life Sciences
19 November 2026 -

China-based biopharmaceutical company Innogen Pharmaceuticals (HKEX: 2591) said on Thursday it has signed an exclusive licensing and commercialisation agreement with Arcera Life Sciences for its internally developed GLP-1 therapy, Efsubaglutide Alfa.

Under the agreement, Arcera will receive exclusive rights to develop and commercialise the product in selected countries across Africa, Eastern Europe, Latin America and the Middle East, while Innogen retains rights in all other markets.

Innogen will receive USD38m in upfront and near-term milestone payments, including a non-refundable upfront payment of USD15m, alongside sales-based milestone payments and tiered royalties of up to double-digit percentages. The companies said the deal has a potential value exceeding USD1bn.

In Innogen's Phase IIb ENLIGHT study in adults with overweight or obesity, participants receiving 20mg once weekly achieved average weight loss of 10.6% after 18 weeks, while those receiving 20mg every two weeks recorded a 9.7% reduction.

The study found improvements in body composition, with the muscle-to-fat ratio increasing by up to 45.3% from baseline and liver fat content declining by up to 51.8% in the once-weekly dosing group. Innogen said the treatment was well tolerated, with no participants discontinuing because of adverse events during the 18-week treatment period.

The company has also completed a Phase II obesity trial in Australia evaluating once-monthly dosing, generating additional clinical data to support future international registration and commercialisation.

The agreement forms part of Innogen's international expansion strategy and marks a further step in the overseas development of Efsubaglutide Alfa.

Login
Username:

Password: